MT 6345
Alternative Names: MT-6345Latest Information Update: 02 Oct 2021
At a glance
- Originator Mitsubishi Tanabe Pharma America
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 25 Jul 2020 Discontinued - Phase-I for Neurological disorders (In volunteers) in United Kingdom (unspecified route) (Mitsubishi Tanabe Pharma Corporation's pipeline, August 2020)
- 15 Jan 2019 Phase-I clinical trials in Unspecified (In volunteers) in United Kingdom (unspecified route) (NCT03809039)